vs
ロジテック（LOGI）とUNITED THERAPEUTICS Corp（UTHR）の財務データ比較。上の社名をクリックして会社を切り替えられます
ロジテックの直近四半期売上が大きい（$1.4B vs $790.2M、UNITED THERAPEUTICS Corpの約1.8倍）。UNITED THERAPEUTICS Corpの純利益率が高く（46.1% vs 17.7%、差は28.4%）。UNITED THERAPEUTICS Corpの前年同期比売上増加率が高い（7.4% vs 6.1%）。ロジテックの直近四半期フリーキャッシュフローが多い（$465.6M vs $173.3M）。過去8四半期でロジテックの売上複合成長率が高い（18.5% vs 8.0%）
ロジテックインターナショナルS.A.はスイス・ローザンヌに本社を置く多国籍企業で、コンピュータ周辺機器とソフトウェアの開発・製造を事業の中心としています。欧州、アジア、オセアニア、米州各地に事業所を設け、スイス市場指数の構成銘柄であるほか、ナスダックにも上場しています。
ユナイテッド・セラピューティクスは米国のバイオテクノロジー企業で、異種移植を含む臓器移植関連の医薬品や技術を開発しています。主力製品の多くは肺疾患治療や臓器製造分野向けで、メリーランド州とノースカロライナ州に2つの本社を置き、米国各地やカナダにも拠点を構えています。
LOGI vs UTHR — 直接比較
損益計算書 — Q3 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $1.4B | $790.2M |
| 純利益 | $251.0M | $364.3M |
| 粗利率 | 43.2% | 86.9% |
| 営業利益率 | 20.1% | 45.1% |
| 純利益率 | 17.7% | 46.1% |
| 売上前年比 | 6.1% | 7.4% |
| 純利益前年比 | 25.4% | 20.9% |
| EPS（希薄化後） | $1.69 | $7.66 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $1.4B | $790.2M | ||
| Q3 25 | $1.2B | $799.5M | ||
| Q2 25 | $1.1B | $798.6M | ||
| Q1 25 | $1.0B | $794.4M | ||
| Q4 24 | $1.3B | $735.9M | ||
| Q3 24 | $1.1B | $748.9M | ||
| Q2 24 | $1.1B | $714.9M | ||
| Q1 24 | $1.0B | $677.7M |
| Q4 25 | $251.0M | $364.3M | ||
| Q3 25 | $170.7M | $338.7M | ||
| Q2 25 | $146.0M | $309.5M | ||
| Q1 25 | $144.1M | $322.2M | ||
| Q4 24 | $200.1M | $301.3M | ||
| Q3 24 | $145.5M | $309.1M | ||
| Q2 24 | $141.8M | $278.1M | ||
| Q1 24 | $167.6M | $306.6M |
| Q4 25 | 43.2% | 86.9% | ||
| Q3 25 | 43.4% | 87.4% | ||
| Q2 25 | 41.7% | 89.0% | ||
| Q1 25 | 43.1% | 88.4% | ||
| Q4 24 | 42.9% | 89.7% | ||
| Q3 24 | 43.6% | 88.9% | ||
| Q2 24 | 42.8% | 89.1% | ||
| Q1 24 | 43.2% | 89.2% |
| Q4 25 | 20.1% | 45.1% | ||
| Q3 25 | 16.1% | 48.6% | ||
| Q2 25 | 14.1% | 45.6% | ||
| Q1 25 | 10.5% | 48.2% | ||
| Q4 24 | 17.5% | 48.6% | ||
| Q3 24 | 14.4% | 45.8% | ||
| Q2 24 | 14.1% | 44.7% | ||
| Q1 24 | 12.9% | 52.6% |
| Q4 25 | 17.7% | 46.1% | ||
| Q3 25 | 14.4% | 42.4% | ||
| Q2 25 | 12.7% | 38.8% | ||
| Q1 25 | 14.3% | 40.6% | ||
| Q4 24 | 14.9% | 40.9% | ||
| Q3 24 | 13.0% | 41.3% | ||
| Q2 24 | 13.0% | 38.9% | ||
| Q1 24 | 16.6% | 45.2% |
| Q4 25 | $1.69 | $7.66 | ||
| Q3 25 | $1.15 | $7.16 | ||
| Q2 25 | $0.98 | $6.41 | ||
| Q1 25 | $0.94 | $6.63 | ||
| Q4 24 | $1.32 | $6.23 | ||
| Q3 24 | $0.95 | $6.39 | ||
| Q2 24 | $0.92 | $5.85 | ||
| Q1 24 | $1.07 | $6.17 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $1.8B | $2.9B |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $2.3B | $7.1B |
| 総資産 | $4.1B | $7.9B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $1.8B | $2.9B | ||
| Q3 25 | $1.4B | $2.8B | ||
| Q2 25 | $1.5B | $3.0B | ||
| Q1 25 | $1.5B | $3.3B | ||
| Q4 24 | $1.5B | $3.3B | ||
| Q3 24 | $1.4B | $3.3B | ||
| Q2 24 | $1.5B | $3.0B | ||
| Q1 24 | $1.5B | $2.7B |
| Q4 25 | $2.3B | $7.1B | ||
| Q3 25 | $2.1B | $6.6B | ||
| Q2 25 | $2.2B | $7.2B | ||
| Q1 25 | $2.1B | $6.8B | ||
| Q4 24 | $2.1B | $6.4B | ||
| Q3 24 | $2.1B | $6.1B | ||
| Q2 24 | $2.2B | $5.7B | ||
| Q1 24 | $2.2B | $5.3B |
| Q4 25 | $4.1B | $7.9B | ||
| Q3 25 | $3.7B | $7.4B | ||
| Q2 25 | $3.7B | $7.9B | ||
| Q1 25 | $3.5B | $7.7B | ||
| Q4 24 | $3.7B | $7.4B | ||
| Q3 24 | $3.6B | $7.1B | ||
| Q2 24 | $3.7B | $6.7B | ||
| Q1 24 | $3.6B | $6.5B |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $480.5M | $346.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $465.6M | $173.3M |
| FCFマージンFCF / 売上 | 32.8% | 21.9% |
| 設備投資強度設備投資 / 売上 | 1.0% | 21.9% |
| キャッシュ転換率営業CF / 純利益 | 1.91× | 0.95× |
| 直近12ヶ月FCF直近4四半期 | $903.6M | $1.0B |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $480.5M | $346.2M | ||
| Q3 25 | $228.8M | $562.1M | ||
| Q2 25 | $125.0M | $191.7M | ||
| Q1 25 | $129.7M | $461.2M | ||
| Q4 24 | $370.9M | $341.2M | ||
| Q3 24 | $166.0M | $377.2M | ||
| Q2 24 | $176.0M | $232.2M | ||
| Q1 24 | $239.1M | $376.5M |
| Q4 25 | $465.6M | $173.3M | ||
| Q3 25 | $212.3M | $351.6M | ||
| Q2 25 | $108.8M | $129.5M | ||
| Q1 25 | $116.9M | $386.3M | ||
| Q4 24 | $356.6M | $254.5M | ||
| Q3 24 | $151.5M | $300.7M | ||
| Q2 24 | $161.4M | $187.1M | ||
| Q1 24 | $228.8M | $338.3M |
| Q4 25 | 32.8% | 21.9% | ||
| Q3 25 | 17.9% | 44.0% | ||
| Q2 25 | 9.5% | 16.2% | ||
| Q1 25 | 11.6% | 48.6% | ||
| Q4 24 | 26.6% | 34.6% | ||
| Q3 24 | 13.6% | 40.2% | ||
| Q2 24 | 14.8% | 26.2% | ||
| Q1 24 | 22.6% | 49.9% |
| Q4 25 | 1.0% | 21.9% | ||
| Q3 25 | 1.4% | 26.3% | ||
| Q2 25 | 1.4% | 7.8% | ||
| Q1 25 | 1.3% | 9.4% | ||
| Q4 24 | 1.1% | 11.8% | ||
| Q3 24 | 1.3% | 10.2% | ||
| Q2 24 | 1.3% | 6.3% | ||
| Q1 24 | 1.0% | 5.6% |
| Q4 25 | 1.91× | 0.95× | ||
| Q3 25 | 1.34× | 1.66× | ||
| Q2 25 | 0.86× | 0.62× | ||
| Q1 25 | 0.90× | 1.43× | ||
| Q4 24 | 1.85× | 1.13× | ||
| Q3 24 | 1.14× | 1.22× | ||
| Q2 24 | 1.24× | 0.83× | ||
| Q1 24 | 1.43× | 1.23× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
LOGI
| Retail Gaming | $482.7M | 34% |
| Retail Keyboards Desktops | $254.6M | 18% |
| Retail Pointing Devices | $241.2M | 17% |
| Retail Video Collaboration | $193.3M | 14% |
| Retail Tablet And Other Accessories | $93.6M | 7% |
| Retail Webcams | $82.3M | 6% |
| Retail Headsets | $45.9M | 3% |
| Other Retail Products | $28.0M | 2% |
UTHR
| Tyvaso DPI | $338.6M | 43% |
| Remodulin | $128.0M | 16% |
| Nebulized Tyvaso | $125.7M | 16% |
| Orenitram | $121.2M | 15% |
| Unituxin | $62.3M | 8% |
| Adcirca | $7.8M | 1% |
| Other | $6.6M | 1% |
